Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of care

Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC

Breast conserving surgery and IORT can manage locally recurrent breast cancer

Overview of cancer health disparities: Current state and future directions

Addressing Breast Cancer Disparities in Africa

Providing equitable cancer care globally

Advocacy for global radiotherapy awareness

Determinants of cancer disparities - Data driven insights from South East Asia